BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34280924)

  • 1. Clonal Megakaryocyte Dysplasia with Normal Blood Values Is a Distinct Myeloproliferative Neoplasm.
    Barosi G; Rosti V; Massa M; Campanelli R; Villani L; Catarsi P; Carolei A; Abbà C; Lodigiani C; Primignani M; Gregato G; Bertolini F; Magrini U; Gale RP
    Acta Haematol; 2022; 145(1):30-37. PubMed ID: 34280924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal Megakaryocyte Dysplasia with Isolated Thrombocytosis Is a Distinct Myeloproliferative Neoplasm Phenotype.
    Barosi G; Campanelli R; Massa M; Catarsi P; Carolei A; Abbà C; Villani L; Magrini U; Gregato G; Bertolini F; de Silvestri A; Gale RP; Rosti V
    Acta Haematol; 2023; 146(1):14-25. PubMed ID: 36349787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives.
    Barosi G; Rosti V; Gale RP
    Leukemia; 2023 Apr; 37(4):725-727. PubMed ID: 36871061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How I Diagnose Primary Myelofibrosis.
    Prakash S; Orazi A
    Am J Clin Pathol; 2022 Apr; 157(4):518-530. PubMed ID: 35238345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Essential thrombocythaemia with mutation in
    Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M
    J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes.
    Alvarez-Larrán A; Ancochea A; García M; Climent F; García-Pallarols F; Angona A; Senín A; Barranco C; Martínez-Avilés L; Serrano S; Bellosillo B; Besses C
    Br J Haematol; 2014 Sep; 166(6):911-9. PubMed ID: 24957246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
    Rumi E; Cazzola M
    Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.
    Merlinsky TR; Levine RL; Pronier E
    Clin Cancer Res; 2019 May; 25(10):2956-2962. PubMed ID: 30655313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms.
    Nomani L; Bodo J; Zhao X; Durkin L; Loghavi S; Hsi ED
    Am J Clin Pathol; 2016 Oct; 146(4):431-8. PubMed ID: 27686170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Calreticulin gene and myeloproliferative neoplasms.
    Clinton A; McMullin MF
    J Clin Pathol; 2016 Oct; 69(10):841-5. PubMed ID: 27354406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate.
    Nielsen C; Bojesen SE; Nordestgaard BG; Kofoed KF; Birgens HS
    Haematologica; 2014 Sep; 99(9):1448-55. PubMed ID: 24907356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
    Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
    J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion.
    Smaili W; Doubaj Y; Laarabi FZ; Lyahyai J; Kerbout M; Mikdame M; Sefiani A
    Curr Res Transl Med; 2017; 65(1):15-19. PubMed ID: 28340692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
    Loghavi S; Bueso-Ramos CE; Kanagal-Shamanna R; Ok CY; Salim AA; Routbort MJ; Mehrotra M; Verstovsek S; Medeiros LJ; Luthra R; Patel KP
    Am J Clin Pathol; 2016 Mar; 145(3):418-27. PubMed ID: 27124925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations.
    Guo BB; Allcock RJ; Mirzai B; Malherbe JA; Choudry FA; Frontini M; Chuah H; Liang J; Kavanagh SE; Howman R; Ouwehand WH; Fuller KA; Erber WN
    Am J Pathol; 2017 Jul; 187(7):1512-1522. PubMed ID: 28502479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR.
    Murugesan G; Guenther-Johnson J; Mularo F; Cook JR; Daly TM
    Int J Lab Hematol; 2016 Jun; 38(3):284-97. PubMed ID: 27018326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
    Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
    Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vascular myeloproliferative neoplasm with normal cell blood count: Exploration and medical management].
    Fourgeaud C; El Nemer W; Michon Pasturel U; Bonhomme S; Brignier A; Lazareth I; Priollet P
    J Mal Vasc; 2015 Dec; 40(6):350-8. PubMed ID: 26362408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.